Searching journal content for articles similar to Kim et al. 23 (10): 813.

Displaying results 1-10 of 16
For checked items
  1. ...and the relationship between PD-L1 expression and clinicopathologic factors including BRAF, TERT promoter status and disease progression were evaluated. Materials and methods Case selection A total of 407 primary thyroid cancers were included (papillary thyroid carcinoma n = 326, follicular thyroid carcinoma n = 66...
  2. ... PW & Xing M 2016 Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncology [in press]. (doi:10.1001/jamaoncol.2016.3288) Muzza M, Colombo C, Rossi S, Tosi...
  3. ...sinology, Diabetes and Metabolism, Correspondence to M Xing Key Words " TERT promoter mutation " thyroid cancer " telomerase reverse transcriptase " BRAF V600E mutation " genetic molecular markers " prognosis " diagnosis Telomerase reverse transcriptase (TERT) is the catalytic Telomerase is well...
  4. ...reverse transcriptase (TERT) expression and activity in thyroid cancers are quite variable, but were estimated to be present in approximately 50% of samples across all subtypes of thyroid cancers from a metaanaylsis (Capezzone et al. 2009). Additionally, mutations in the TERT promoter region occurred...
  5. ...differentiated thyroid cancer (PDTC), although this type of thyroid cancer is obviously characterized by a high risk of relapse and a bad prognosis. Moreover, Hurthle cell carcinoma (HCC, oncocytic variant of follicular carcinoma) was mentioned in the description of recommendation 46 concerning the basic...
  6. ...often in patients at third decade of life (Pillai et al. 2015). Thus, both CMV-PTC and diffuse sclerosing variant of papillary thyroid carcinoma should be considered in thyroid cancer detected in young adults. From the accumulated data in the literature, CMV-PTC occurs in a slightly younger age than...
  7. ...–3116. (doi:10.1210/jc.2008-0273) Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603–610. (doi:10.1530/ERC-13-0210) Love MI, Huber W & Anders S 2014 Moderated estimation...
  8. ...Rengyun Liu and Mingzhao Xing to M Xing Email [email protected] FNAB, demonstrating the value of this novel molecular testing in the diagnosis of thyroid Key Words " TERT promoter mutation " thyroid cancer " fine needle aspiration biopsy " BRAF V600E mutation " telomerase reverse transcriptase...
  9. ....1677/.1.00892) Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar A & Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603–610. (doi:10.1530/ ERC-13-0210) Ma C, Kuang A, Xie J & Ma T 2005 Possible explanations for patients...
  10. ...-Related Cancer (2013) 20, 603–610 Research X Liu et al. TERT promoter mutations in thyroid cancers 20 :4 603–610prevalent in the aggressive thyroid cancers TCPTC, PDTC, ATC and BRAF mutation-positive PTC, revealing a novel genetic background for thyroid cancers.thyroid cancers (PDTC), 23 of 54 (42.6%) anaplastic...
For checked items